[1]Lugo L, Villalvilla A,Largo R.Selective estrogen receptor modulators (SERMs): New alternatives for osteoarthritis? Maturitas. 2014;77(4):380-384.
[2]Felson DT, Neogi T.Osteoarthritis: is it a disease of cartilage or of bone?Arthritis Rheum 2004;50:341-344.
[3]Wang P, Liu C, Yang XT, et al.Effect of extracorporeal shock wave therapy on cartilage and subchondral bone remodeling in rabbits with ACLT-induced osteoarthritis. 2014;45(1):120-125.
[4]Henrotin Y, Lambert C, Richette P.Importance of synovitis in osteoarthritis: Evidence for the use of glycosaminoglycans against synovial inflammation.Semin Arthritis Rheum. 2013.
[5]Bay-Jensen AC,Hoegh-Madsen S,Dam E,et al.Which elements are involved in reversible and irreversible cartilage degradation in osteoarthritis?Rheumatol Int 2010;30:435-442.
[6]Karsdal MA, Madsen SH, Christiansen C,et al.Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. Arthritis Res Ther. 2008;10:R63. Epub 30 May 2008
[7]Wang QP, Yang L, Li XP,et al.Effects of 17β-estradiol on adiponectin regulation of the expression of osteoprotegerin and receptor activator of nuclear factor-κB ligand.Bone. 2012; 51(3):515-523.
[8]Rafeey M, Ghorbanihaghjo A, Masoumi F,et al.New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target?Iran Red Crescent Med J. 2013;15(10):e7591.
[9]Shevde LA,Samant RS,et al.Loss of N-Myc interactor promotes epithelial-mesenchymal transition by activation of TGF-β/SMAD signaling. Oncogene. 2013 Jun 17.doi: 10.1038/onc.2013.215.
[10]Xu Yong, Yang Hua, Qiao Jian-Ou, et al.High-bone-turnover Osteoporosis and Aortic Calcification in Opg Knockout Mice. Progress in Biochemistry and Biophysics.2007;34(3):260-266.
[11]Wang YD, Tao MF, Wang L,et al.Selective regulation of osteoblastic OPG and RANKL by dehydroepiandrosterone through activation of the estrogen receptor β-mediated MAPK signaling pathway.Horm Metab Res.2012;44(7):494-500.
[12]West SL, Lok CE, Jamal SA.Osteoprotegerin and fractures in men and women with chronic kidney disease.J Bone Miner Metab. 2013 Oct 11.
[13]Weitzmann MN.The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis.Scientifica (Cairo).2013;2013:125705.
[14]Sorensen MG, Henriksen K, Dziegiel MH,et al. Estrogen directly attenuates human osteoclastogenesis, but has no effect on resorption by mature osteoclasts.DNA Cell Biol. 2006;25:475-483.
[15]Eghbali-Fatourechi G, Khosla S, Sanyal A,et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women.J Clin Invest.2003;111:1221-1230.
[16]Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.JAMA 2004;292:490-495.
[17]Proff PR.The molecular mechanism behind bone remodelling a review. Clin Oral Investig.2009;13(4)355-362.
[18]Hopwood B, Tsykin AFindlay DM,et al.Microarray gene expression profiling of osteoarthritic bone suggests altered bone remodelling WNT and transforming growth factorbeta/ bone morphogenic protein signalling J.Arthritis Res Ther. 2007; 9(5):100-120.
[19]Tanko LB, Sondergaard BC, Oestergaard S,et al. An update review of cellular mechanisms conferring the indirect and direct effects of estrogen on articular cartilage. Climacteric. 2008;11:4-16.
[20]Jilka RL, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science.1992;257(5):88-91.
[21]Kimble RB,Srivastava S,Ross FP,et al.Estrogen deficiency increases the ability of stromal cells to support murine osteoclastogenesis via an interleukin-1and tumor necrosis factor-mediated stimulation of macrophage colony-stimulating factor production.J Biol Chem.1996;271(46):28890-28897.
[22]Ray A,Prefontaine KE,Ray P,et al.Down.modulation of interleukin-6 gene expression bv17 beta estradlol in the absence of high affinity DNA binding by the estrogen receptor. J Biol Chem.1994;269(17):12940-12946.
[23]万荣,杨庆铭.邓廉夫,等.不同浓度雌激素对软骨细胞金属蛋白酶 mRNA表达的影响[J].中华风湿病学杂志,2002,6(3):174.7.
[24]RicheRe P,Dumontier MF,Francois M,et al.Dual effects of 17β-oestradiol on interleukin-1β.induced proteoglycan degradation in chondrocytes.Ann Rheum Dis. 2004;63(2): 191-199.
[25]Lee YJ,Lee EB,Kwon YE,et al.Effect of estrogen on the expression of matrix metalloproteinase MMP-1,MMP-3,and MMP-13 and tissue inhibitor of metalloprotemase-1in osteoarthritis chondre cytes.Rheu-matol Intern. 2003:23(6): 282-288.
[26]Ham KD, Loeser RF, Lindgren BR,et al. Effects of long-term estrogen replacement therapy on osteoarthritis severity in cynomolgus monkeys.Arthritis Rheum, 2002;46:1956-1964.
[27]Oestergaard S, Sondergaard BC, Hoegh-Andersen P,et al.Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation.Arthritis Rheum 2006;54:2441-2451.
[28]Yang JH, Kim JH, Lim DS,et al.Effect of combined sex hormone replacement on bone/cartilage turnover in a murine model of osteoarthritis.Clin Orthop Surg. 2012;4(3):234-241.
[29]Calvo E, Castaneda S, Largo R, et al.Osteoporosis increases the severity of cartilage damage in an experimental model of osteoarthritis in rabbits.Osteoarthritis Cartilage. 2007;15:69-77.
[30]Ma HL, Blanchet TJ, Peluso D, et al.Osteoarthritis severity is sex dependent in a surgical mouse model.Osteoarthritis Cartilage. 2007;15:695-700.
[31]Christgau S, Tanko LB, Cloos PA,et al.Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen- receptor modulator (SERM). Menopause. 2004;11:508-518.
[32]Cirillo DJ, Wallace RB, Wu L, et al.Effect of hormone therapy on risk of hip and knee joint replacement in the Women’s Health Initiative.Arthritis Rheum. 2006;54:3194-3204.
[33]Kerin A, Patwari P, Kuettner K,et al.Molecular basis of osteoarthritis: biomechanical aspects.Cell Mol Life Sci 2002; 59:27-35.
[34]Michael H, Harkonen PL, Kangas L,et al.Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclastsin vitro. Br J Pharmacol.2007;151:384-395. |